Impax responds to reports about generic Lipitor

HAYWARD, Calif. — In response to articles that appeared in several media outlets about its generic drug pipeline, drug maker Impax Labs is looking to set the record straight.

The company said several financial websites had reported that Impax had found a way to make a generic version of Pfizer’s cholesterol-lowering drug Lipitor (atorvastatin calcium).

The company said that while it had 98 generic drugs in its development pipeline and had filed for approval for 36 drugs with the Food and Drug Administration, it had not filed an application for a generic version of Lipitor and did not have an agreement with any company to produce it.